travoprost rafarm 40 mcg/ml
مستودع أدوية الغروب - sun set drug store - travoprost 40 mcg/ml - 40 mcg/ml
travoprost eg 40 µg/ml eye drops sol. dropper cont.
eg sa-nv - travoprost 0,04 mg/ml - eye drops, solution - travoprost
travoprost 0.004% eye drops
beximco pharmaceuticals ltd. - travoprost - eye drops - 4 mg/100 ml
travoprost ophthalmic solution 0.004% "nitto" (トラボプロスト点眼液0.004%「ニットー」)
nitto medic co., ltd. - travoprost - colorless to pale yellow limpid ophthalmic solution, (cap) light purple, (label) clear, (bottle) clear
sandoz travoprost / timolol pq solution
sandoz canada incorporated - travoprost; timolol (timolol maleate) - solution - 0.004%; 0.5% - travoprost 0.004%; timolol (timolol maleate) 0.5% - beta-adrenergic agents
apo-travoprost-timop pq solution
apotex inc - travoprost; timolol (timolol maleate) - solution - 0.004%; 0.5% - travoprost 0.004%; timolol (timolol maleate) 0.5% - beta-adrenergic agents
travoprost/timolol sandoz 40/5 travoprost 40 microgram/ml and timolol (as maleate) 5 mg/ml eye drop solution bottle
novartis pharmaceuticals australia pty ltd - timolol maleate,travoprost -
bondulc 40 micrograms/ml eye drops, solution
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - travoprost - eye drops, solution - travoprost 40 µg/ml - ophthalmologicals
travatan z- travoprost solution/ drops
novartis pharmaceuticals corporation - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travatan z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is
travon eye drops
indoco remedies limited "indoco house, 166, cst road, santacruz (east), - travoprost - eye drops - each ml contains: travoprost 0.04 mg - travoprost